MA53124A - Agents de dégradation sélectifs des récepteurs des oestrogènes - Google Patents

Agents de dégradation sélectifs des récepteurs des oestrogènes

Info

Publication number
MA53124A
MA53124A MA053124A MA53124A MA53124A MA 53124 A MA53124 A MA 53124A MA 053124 A MA053124 A MA 053124A MA 53124 A MA53124 A MA 53124A MA 53124 A MA53124 A MA 53124A
Authority
MA
Morocco
Prior art keywords
eestrogen
receptor
selective degradation
degradation agents
agents
Prior art date
Application number
MA053124A
Other languages
English (en)
Other versions
MA53124B1 (fr
Inventor
Jolie Anne Bastian
Jeffrey Daniel Cohen
Almudena Rubio
Daniel Jon Sall
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=67470734&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA53124(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MA53124A publication Critical patent/MA53124A/fr
Publication of MA53124B1 publication Critical patent/MA53124B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Finger-Pressure Massage (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
MA53124A 2018-07-12 2019-07-11 Agents de dégradation sélectifs des récepteurs des oestrogènes MA53124B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862697100P 2018-07-12 2018-07-12
PCT/US2019/041334 WO2020014435A1 (fr) 2018-07-12 2019-07-11 Agents de dégradation sélectifs des récepteurs des oestrogènes

Publications (2)

Publication Number Publication Date
MA53124A true MA53124A (fr) 2021-05-19
MA53124B1 MA53124B1 (fr) 2023-02-28

Family

ID=67470734

Family Applications (2)

Application Number Title Priority Date Filing Date
MA53124A MA53124B1 (fr) 2018-07-12 2019-07-11 Agents de dégradation sélectifs des récepteurs des oestrogènes
MA53126A MA53126B1 (fr) 2018-07-12 2019-07-11 Agents de dégradation sélectifs du récepteur des oestrogènes

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA53126A MA53126B1 (fr) 2018-07-12 2019-07-11 Agents de dégradation sélectifs du récepteur des oestrogènes

Country Status (37)

Country Link
US (4) US10654866B2 (fr)
EP (2) EP4155310A1 (fr)
JP (6) JP6995241B2 (fr)
KR (3) KR102783756B1 (fr)
CN (2) CN112638916B (fr)
AR (2) AR115694A1 (fr)
AU (2) AU2019299947B2 (fr)
BR (1) BR122023025061A2 (fr)
CA (1) CA3105501C (fr)
CL (1) CL2021000045A1 (fr)
CO (1) CO2021000043A2 (fr)
CR (1) CR20210007A (fr)
DK (1) DK3820873T3 (fr)
EA (1) EA202092975A1 (fr)
EC (1) ECSP21001770A (fr)
ES (1) ES2933980T3 (fr)
FI (1) FI3820873T3 (fr)
HR (1) HRP20230009T1 (fr)
HU (1) HUE060963T2 (fr)
IL (3) IL289871B2 (fr)
JO (1) JOP20210005A1 (fr)
LT (1) LT3820873T (fr)
MA (2) MA53124B1 (fr)
MD (1) MD3820873T2 (fr)
MX (2) MX2021000375A (fr)
MY (1) MY198962A (fr)
PE (1) PE20210400A1 (fr)
PH (1) PH12021550049A1 (fr)
PL (1) PL3820873T3 (fr)
PT (1) PT3820873T (fr)
RS (1) RS63809B1 (fr)
SA (1) SA521421008B1 (fr)
SG (1) SG11202100148TA (fr)
SI (1) SI3820873T1 (fr)
TW (1) TWI702219B (fr)
UA (1) UA127507C2 (fr)
WO (1) WO2020014435A1 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA122346C2 (uk) 2015-10-01 2020-10-26 Олема Фармасьютикалз, Інк. ТЕТРАГІДРО-1H-ПІРИДО[3,4-b]ІНДОЛЬНІ АНТИЕСТРОГЕННІ ЛІКАРСЬКІ ПРЕПАРАТИ
WO2020014440A1 (fr) * 2018-07-12 2020-01-16 Eli Lilly And Company Agents de dégradation sélectifs du récepteur des oestrogènes
TWI702219B (zh) * 2018-07-12 2020-08-21 美商美國禮來大藥廠 選擇性雌激素受體降解劑
JP7616794B2 (ja) 2019-07-07 2025-01-17 オレマ ファーマシューティカルズ インク． エストロゲン受容体アンタゴニストのレジメン
IL293252A (en) 2019-12-09 2022-07-01 Sanofi Sa Crystalline form of a 7h-benzo[7]annulene-2-carboxylic acid derivative
TW202146007A (zh) 2020-02-27 2021-12-16 法商賽諾菲公司 包含阿培利司（ａｌｐｅｌｉｓｉｂ）與６－（２，４－二氯苯基）－５－［４－［（３ｓ）－１－（３－氟丙基）吡咯啶－３－基］氧苯基］－８，９－二氫－７ｈ－苯并［７］輪烯－２－羧酸之組合
IL303041A (en) * 2020-11-23 2023-07-01 Sanofi Sa Combination comprising abemaciclib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid
AU2022222660A1 (en) * 2021-02-16 2023-07-27 Genentech, Inc. Treatment of breast cancer using combination therapies comprising gdc-9545 and abemaciclib or ribociclib
CN114957114A (zh) * 2021-02-26 2022-08-30 冷志 一种4-溴-3-氯-7-甲氧基喹啉的合成方法
CN117042771A (zh) * 2021-03-09 2023-11-10 伊莱利利公司 使用serd给药方案的组合治疗癌症的方法
TWI837605B (zh) * 2021-03-09 2024-04-01 美商美國禮來大藥廠 使用serd組合給藥方案治療癌症之方法
TWI894443B (zh) * 2021-03-16 2025-08-21 美商美國禮來大藥廠 選擇性雌激素受體降解劑
AU2023216654B2 (en) * 2022-02-01 2025-09-25 Eli Lilly And Company Processes for the preparation of selective estrogen receptor degraders
TW202430176A (zh) 2022-10-17 2024-08-01 瑞典商阿斯特捷利康公司 用於治療癌症之組合療法
CN120456897A (zh) 2022-11-02 2025-08-08 佩特拉制药公司 用于治疗疾病的磷酸肌醇3-激酶(pi3k)变构色原酮抑制剂
CN120187416A (zh) 2022-11-11 2025-06-20 阿斯利康(瑞典)有限公司 用于治疗癌症的组合疗法
US20240180893A1 (en) 2022-11-17 2024-06-06 Astrazeneca Ab Methods of treatment of breast cancer
AU2024268541A1 (en) 2023-05-05 2025-11-20 Eli Lilly And Company Imlunestrant or salts thereof for use in treating and preventing central nervous system (cns) metastases in subjects having er+ breast cancer
AU2024268579A1 (en) 2023-05-11 2026-01-15 Astrazeneca Ab Combination of a parp1 inhibitor and a selective estrogen degrader for treating cancer

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1395563B1 (fr) * 2001-05-22 2006-03-29 Eli Lilly And Company 1,2,3,4-tetrahydroquinoline 2-substituees et leurs derives, ainsi que leurs composition et leurs procedes
US7329654B2 (en) * 2001-12-19 2008-02-12 Janssen Pharmaceutica N.V. Heteroatom containing tetracyclic derivatives as selective estrogen receptor modulators
MXPA04010433A (es) * 2002-04-19 2005-08-19 Signal Pharm Inc Compuestos benzopiranona, composiciones de estos y los metodos para el tratamiento con estos.
US20090023917A1 (en) * 2004-01-22 2009-01-22 Eli Lilly And Company Selective Estrogen Receptor Modulators for the Treatment of Vasomotor Symptoms
US20080221163A1 (en) * 2005-01-18 2008-09-11 Jeffrey Alan Dodge Selective Estrogen Receptor Modulators
BR112015030595A2 (pt) 2013-06-19 2017-07-25 Seragon Pharmaceuticals Inc moduladores de receptor de estrogênio de azetidina e usos dos mesmos
EP3233828B1 (fr) * 2014-12-18 2020-03-04 F. Hoffmann-La Roche AG Modulateurs des recepteurs des oestrogenes et leurs utilisations
IL301960B2 (en) * 2014-12-18 2024-08-01 Hoffmann La Roche Tetrahydro-pyrido[3, 4-b]indole estrogen receptor modulators and their uses
WO2018108954A1 (fr) 2016-12-12 2018-06-21 F. Hoffmann-La Roche Ag Procédé de préparation de 2-(3-(fluorométhyl)azétidin-1-yl)éthan-1-ol
WO2020014440A1 (fr) * 2018-07-12 2020-01-16 Eli Lilly And Company Agents de dégradation sélectifs du récepteur des oestrogènes
TWI702219B (zh) * 2018-07-12 2020-08-21 美商美國禮來大藥廠 選擇性雌激素受體降解劑

Also Published As

Publication number Publication date
FI3820873T3 (fi) 2023-03-02
IL280065B (en) 2022-04-01
MD3820873T2 (ro) 2023-05-31
JP2025186400A (ja) 2025-12-23
EP4155310A1 (fr) 2023-03-29
UA127507C2 (uk) 2023-09-13
JP2021530484A (ja) 2021-11-11
JP2022050591A (ja) 2022-03-30
BR122023025061A2 (pt) 2024-02-20
CR20210007A (es) 2021-02-08
AU2022203969A1 (en) 2022-06-30
IL295598B1 (en) 2023-05-01
US10654866B2 (en) 2020-05-19
IL289871A (en) 2022-03-01
SG11202100148TA (en) 2021-02-25
JP2023081954A (ja) 2023-06-13
SA521421008B1 (ar) 2022-10-30
PT3820873T (pt) 2022-12-23
KR20210019065A (ko) 2021-02-19
CN112638916A (zh) 2021-04-09
ES2933980T3 (es) 2023-02-15
IL280065A (en) 2021-03-01
LT3820873T (lt) 2023-01-10
MA53126B1 (fr) 2023-02-28
MA53126A (fr) 2021-05-19
SI3820873T1 (sl) 2023-02-28
MA53124B1 (fr) 2023-02-28
RS63809B1 (sr) 2023-01-31
IL289871B2 (en) 2023-02-01
PL3820873T3 (pl) 2023-02-13
CN112638916B (zh) 2023-09-12
AU2022203969B2 (en) 2024-02-15
NZ771718A (en) 2024-05-31
US11634426B2 (en) 2023-04-25
TW202019935A (zh) 2020-06-01
IL289871B (en) 2022-10-01
JP2022037102A (ja) 2022-03-08
AU2019299947A1 (en) 2021-01-07
TWI702219B (zh) 2020-08-21
US20200347073A1 (en) 2020-11-05
JOP20210005A1 (ar) 2021-01-10
CN117379428A (zh) 2024-01-12
US20210403480A1 (en) 2021-12-30
JP2024169490A (ja) 2024-12-05
US11117902B2 (en) 2021-09-14
DK3820873T3 (da) 2022-12-12
KR20230005404A (ko) 2023-01-09
BR112020025654A2 (pt) 2021-04-06
JP7241211B2 (ja) 2023-03-16
MY198962A (en) 2023-10-05
AR134487A2 (es) 2026-01-21
MX2023006047A (es) 2023-06-02
US11993608B2 (en) 2024-05-28
JP7557564B2 (ja) 2024-09-27
KR102783756B1 (ko) 2025-03-21
PH12021550049A1 (en) 2021-09-20
WO2020014435A1 (fr) 2020-01-16
KR20230148386A (ko) 2023-10-24
HUE060963T2 (hu) 2023-04-28
PE20210400A1 (es) 2021-03-02
KR102550538B1 (ko) 2023-07-04
US20230234960A1 (en) 2023-07-27
EA202092975A1 (ru) 2021-04-14
HRP20230009T1 (hr) 2023-02-17
IL295598B2 (en) 2023-09-01
JP7009672B1 (ja) 2022-01-25
IL295598A (en) 2022-10-01
CA3105501C (fr) 2023-10-31
JP7746496B2 (ja) 2025-09-30
ECSP21001770A (es) 2021-02-26
CL2021000045A1 (es) 2021-07-19
CO2021000043A2 (es) 2021-01-18
KR102589886B1 (ko) 2023-10-17
AU2019299947B2 (en) 2022-03-17
AR115694A1 (es) 2021-02-17
MX2021000375A (es) 2021-05-27
EP3820873A1 (fr) 2021-05-19
JP6995241B2 (ja) 2022-01-14
US20200017516A1 (en) 2020-01-16
EP3820873B1 (fr) 2022-11-23
CA3105501A1 (fr) 2020-01-16

Similar Documents

Publication Publication Date Title
MA53124A (fr) Agents de dégradation sélectifs des récepteurs des oestrogènes
EP3897631A4 (fr) Dégradation ciblée de protéines
EP3860183A4 (fr) Dispositif de relais
DK3687994T3 (da) Gadolinium-bærende pcta-baserede kontrastmidler
DK3762380T3 (da) Phenylpyrrolidinon-formylpeptid-2-receptoragonister
IL268824A (en) Improved antigen binding receptor formats
PL3660004T3 (pl) Związki i sposoby do ukierunkowanej degradacji receptora androgenowego
EP3521427A4 (fr) Co-récepteur de récepteur odorant
ES1243880Y (es) Cepillo de dientes
EP3876986A4 (fr) Immunotolérance ciblée
EP3801134A4 (fr) Agencement de siège
DE112020001082A5 (de) Löschvorrichtung
EP3763567A4 (fr) Siège
EP3523315A4 (fr) Inhibiteurs de récepteurs glucocorticoïdes
MA52555A (fr) Modulateurs du récepteur des oestrogènes
EP3772318C0 (fr) Hystéroscope
DK3412840T3 (da) Toilet
EP3790528A4 (fr) Composition de désinfectant sous forme de mousse
EP3899155A4 (fr) Raccord amélioré
DK3649043T3 (da) Flugtsystem
DK3621871T3 (da) Flugtsystem
DK3453805T3 (da) Skyllevandsfordeler
EP3854794A4 (fr) Agoniste de tlr8
EP3811824A4 (fr) Siège
MA53666A (fr) Purification de stérol